Akari Therapeutics is advancing its research on a novel spliceosome modulator, PH1, which has shown potential in killing cancer cells and activating the immune system. The company is focusing on the ...
Leading cancer researchers from UC San Francisco presented talks about advances in targeted therapies, cancer genomics, using AI to personalize cancer treatment, improving diagnosis of hard-to-treat ...
Elana Thieme and Mark Mendoza, fourth-year graduate students in the Molecular and Cell Biology (MCB) PhD Program jointly ...
Akari Therapeutics has announced the issuance of Patent No. 562,919 for its PH1 payload, a differentiated spliceosome inhibitor aimed at disrupting RNA splicing to induce cancer cell death and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback